6th global Biopharma CEO / top execs virtual press briefings – COVID-19
For any questions, please contact:
COVID-19 response – innovation, manufacturing, and equitable access of vaccines, treatments and their supplies
Organized by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) – representing the global innovative biopharmaceutical industry committed to addressing the novel coronavirus public health crisis.
Dr. Albert Bourla leads Pfizer in its purpose: Breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health.
During his more than 25 years at Pfizer, he has held several senior global positions across a range of markets and disciplines. Before becoming CEO, he served as COO, overseeing commercial strategy, manufacturing, and global product development.
Previously, he served as Group President of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups.
He also created the Patient and Health Impact group, dedicated to increasing patient access, demonstrating the value of Pfizer’s medicines, and broader business model innovation. Prior to that, he was president and General Manager of the Established Products business.
Albert is a Doctor of Veterinary Medicine with a Ph.D. from the Veterinary School of Aristotle University and began his Pfizer career in 1993 in the Animal Health division. In 2020, he was ranked America’s top CEO in the pharmaceuticals sector by Institutional Investor magazine.
He is on the executive committee of the Partnership for New York City, a trustee of the US Council for International Business, a vice-chair of the IFPMA CEO Steering Committee, and a director on multiple boards, including Pfizer Inc., the Pfizer Foundation, PhRMA, and Catalyst.
Belén Garijo is the Chair of the Executive Board and CEO of Merck. She joined Merck in 2011 as Chief Operating Officer of the Biopharma business, becoming President and CEO of Healthcare in 2015. Before taking her current office in May 2021, Belén Garijo served as Vice-Chair of the Executive Board and Deputy CEO.
Under her leadership of the Healthcare business, Merck became a key global player in oncology, immunology, and immuno-oncology. This success followed her repositioning of the portfolio, the reorganization of R&D and the realignment of the commercial model. In addition, Belén Garijo forged two major global alliances that further contributed to the value of the Healthcare portfolio. She also focused on the globalization of the business to expand Merck`s position within the U.S., Japan, and other high-growth markets.
Before joining Merck, Belén Garijo served as the Senior Vice President of Global Operations Europe at Sanofi-Aventis and Global Integration Leader of Genzyme after its acquisition by Sanofi. She previously held several local and global executive positions, both in R&D and commercial, at various companies at the forefront of the healthcare sector.
Belén Garijo is a medical doctor specializing in clinical pharmacology. She started her career as a practicing physician at La Paz hospital in Madrid, Spain, before moving into the pharmaceutical industry.
Belén Garijo was born on July 31, 1960 in Almansa, Spain. She is married and has two daughters.
Paul Stoffels is a visionary leader who inspires and drives transformational innovation to bring years of life and quality of life to millions of people around the world.
Paul spearheads the Johnson & Johnson research and product pipeline by leading teams across all our sectors to set the companywide innovation agenda, discovering and developing transformational healthcare solutions. He also is responsible for the safety of all products of the Johnson & Johnson Family of Companies worldwide, and steers the company’s global public health strategy to make innovative medicines and technologies accessible in the world’s most vulnerable communities and resource-poor settings.
Paul’s commitment to fueling innovation and finding the best science, wherever it exists, is the driving force behind the launch of Johnson & Johnson Innovation in 2013, which he now leads to foster science and technology through strategic partnerships, licensing and acquisitions. Paul also oversees JJDC, the oldest corporate venture fund in the life science industry.
Previously, in his role as Worldwide Chairman, Pharmaceuticals, Paul led the transformation of the pharmaceutical research and development pipeline for Janssen Pharmaceutical Companies of Johnson & Johnson, driving a fundamental shift in the R&D paradigm that is now a model in the industry for productivity and innovation. Under his leadership, Janssen rejuvenated its pipeline, launching multiple new medicines and making a difference for people all over the world.
Prior to this, Paul held various R&D leadership roles within the pharmaceutical sector of Johnson & Johnson. He joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec, and led the development of several breakthrough products for the treatment of HIV that helped to transform this devastating disease from a death sentence to a chronic and treatable condition.
Paul studied Medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium. He began his career as a physician in Africa, focusing on HIV and tropical diseases research.
Bill Anderson is the CEO of Roche Pharmaceuticals. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.
Bill serves as a member of Roche’s Executive Committee, overseeing the Pharmaceutical division.
Leading an organisation of 55,000 people, he is passionate about helping people make meaningful progress every day on the things that matter to patients. With a world-leading investment in R&D, his vision is to bring more medical advances to patients at less cost to society.
His tenure at Roche has seen him serve as the CEO of Genentech, the Head of Global Product Strategy and in roles leading the US Oncology and Immunology business units. Bill has a bachelor’s degree in chemical engineering from the University of Texas and earned masters degrees in management and chemical engineering from the Massachusetts Institute of Technology.
As Director General, Thomas leads IFPMA’s mission to encourage the development of sustainable solutions that enable innovation and improve global health.
Over the past two decades, Thomas has been instrumental in developing collaborative solutions for some of the greatest global health challenges. These include HIV/AIDS and antimicrobial resistance, as well as the industry’s response to pandemics.
He is frequently called upon to comment on industry’s contribution to global health in the world media and at international fora.
Since he joined IFPMA, Thomas has pioneered collaborative solutions to tackle antimicrobial resistance (AMR), chairing the AMR Industry Alliance and launching the AMR Action Fund. This is a USD 1 billion venture begun in July 2020 to fund the development of between two and four new antibiotics by 2030.
Thomas represents the innovative pharmaceutical industry in the Access to COVID-19 Tools (ACT) Accelerator initiative, set up in April 2019. In 2022, together with industry CEOs and building on the lessons learned from COVID-19, he led the development of the Berlin Declaration. This is a vision for equitable access in global pandemic response that invites multilateral organizations as well as the G7 and G20 to agree to a social contract for future health security.
He is Chair of the Business at OECD Health Committee and serves as Industry Co-Chair of the APEC Biopharmaceutical Working Group on Ethics.
Rasmus is a globally recognised expert on scientific information and knowledge dissemination. He spent his earlier career as a Fortune500 strategist.
Rasmus is a strong believer in the power of accurate information and new ideas – he founded his first, short lived, newspaper at the age of 13 – a passion that drove him to found Airfinity.
As CEO of Airfinity he is often quoted in leading media companies such as Financial times, Bloomberg and CNN. He is a board member of the newspaper group, Information.dk. Rasmus holds a B.Sc. in Political Science, a MPA from Harvard University and is a recipient of the Crown Prince Frederic award for excellent scholarship. He lives in London.
Momentum of COVID-19 vaccine manufacturing scale up sufficient for step change in distribution
This month COVID-19 vaccine manufacturing output will pass the 7.5 billion dose mark. Vaccine manufacturers worldwide are now producing 1.5 billion doses per month and this is expected to continue growing. 12 billion vaccines will be produced by the end of 2021 and if there are no major bottlenecks, by June 2022 total vaccine production...Read more